{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NPDR+-+Non+Proliferative+Diabetic+Retinopathy",
    "query": {
      "condition": "NPDR - Non Proliferative Diabetic Retinopathy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NPDR+-+Non+Proliferative+Diabetic+Retinopathy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T05:24:44.938Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01880372",
      "title": "The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Moderate Non-proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Alpha Lipoic Acid",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Ferris State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2013-09",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 2,
      "location_summary": "Big Rapids, Michigan • Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Big Rapids",
          "state": "Michigan"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01880372"
    },
    {
      "nct_id": "NCT07354477",
      "title": "Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-proliferative Diabetic Retinopathy (NPDR)",
        "Open-angle Glaucoma (OAG)",
        "Normal Tension Glaucoma (NTG)"
      ],
      "interventions": [
        {
          "name": "QLS-111 Ophthalmic Solution (0.015%)",
          "type": "DRUG"
        },
        {
          "name": "QLS-111 Ophthalmic Solution (0.075%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Qlaris Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2026-02-20",
      "completion_date": "2026-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07354477"
    },
    {
      "nct_id": "NCT05393284",
      "title": "Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-proliferative Diabetic Retinopathy",
        "Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "OPL-0401 Dose 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valo Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2022-08-16",
      "completion_date": "2024-08",
      "has_results": false,
      "last_update_posted_date": "2024-06-17",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 25,
      "location_summary": "Mountain View, California • Riverside, California • Sacramento, California + 20 more",
      "locations": [
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05393284"
    },
    {
      "nct_id": "NCT02718326",
      "title": "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Nonproliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection [IAI]",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 402,
      "start_date": "2016-03-29",
      "completion_date": "2019-07-16",
      "has_results": true,
      "last_update_posted_date": "2020-07-30",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 71,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718326"
    },
    {
      "nct_id": "NCT04702048",
      "title": "Evaluation of the Retina in Patients With Non-proliferative Diabetic Retinopathy After Aflibercept Injection in the Eye",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinopathy, Diabetic"
      ],
      "interventions": [
        {
          "name": "Aflibercept Injection",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2021-02-01",
      "completion_date": "2024-02-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04702048"
    },
    {
      "nct_id": "NCT04661358",
      "title": "Fenofibrate for Prevention of DR Worsening",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jaeb Center for Health Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 560,
      "start_date": "2021-03-05",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-13",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 66,
      "location_summary": "Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04661358"
    },
    {
      "nct_id": "NCT03197870",
      "title": "The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonproliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "AKB-9778",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EyePoint Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 167,
      "start_date": "2017-06-09",
      "completion_date": "2019-02-09",
      "has_results": true,
      "last_update_posted_date": "2023-06-27",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 53,
      "location_summary": "Phoenix, Arizona • Arcadia, California • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03197870"
    },
    {
      "nct_id": "NCT01552408",
      "title": "Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "0.3 mg ranibizumab",
          "type": "DRUG"
        },
        {
          "name": "Targeted Pan Retinal Photocoagulation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "David M. Brown, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2012-03",
      "completion_date": "2017-05-18",
      "has_results": true,
      "last_update_posted_date": "2018-10-05",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • Katy, Texas • The Woodlands, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Katy",
          "state": "Texas"
        },
        {
          "city": "The Woodlands",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552408"
    },
    {
      "nct_id": "NCT07235085",
      "title": "A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Proliferative Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "Single intravitreal injection of axitinib hydrogel implant followed by a mock (sham) injection procedure at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal injection of axitinib hydrogel implant followed by a second intravitreal injection of the axitinib implant at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Sham/mock procedure of intravitreal injection followed by a second sham/mock procedure at Week 24",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Ocular Therapeutix, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 930,
      "start_date": "2025-11-17",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 1,
      "location_summary": "Hagerstown, Maryland",
      "locations": [
        {
          "city": "Hagerstown",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07235085"
    },
    {
      "nct_id": "NCT02681809",
      "title": "A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Retinopathy",
        "Posterior Vitreous Detachment",
        "Disease Progression"
      ],
      "interventions": [
        {
          "name": "ocriplasmin 0.0625mg",
          "type": "DRUG"
        },
        {
          "name": "ocriplasmin 0.125mg",
          "type": "DRUG"
        },
        {
          "name": "Sham injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ThromboGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2015-12",
      "completion_date": "2019-11-18",
      "has_results": true,
      "last_update_posted_date": "2020-12-16",
      "last_synced_at": "2026-06-10T05:24:44.938Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Campbell, California • Irvine, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Campbell",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02681809"
    }
  ]
}